PET/CT

Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.

Inflammation-targeting PET method predicts recovery after heart attack
Targeting CXCR4 during PET scans could help providers gain vital information regarding patients' potential to fully recover from myocardial infarction.
Nuclear cardiology expands beyond perfusion imaging as it enters a new era
Beyond amyloidosis, nuclear cardiology is also increasingly used to image inflammation and infection in the myocardium, especially in diseases such as cardiac sarcoidosis and myocarditis.
PET holds promise for carotid plaque assessments
PET has already gained significant momentum in recent years. Now, researchers are pointing to another possible use for the popular imaging modality: assessing carotid artery atherosclerosis.
Imaging offers insight into impact of new Alzheimer's treatment from Eli Lilly
Emerging research provides further evidence that amyloid-removal treatment for Alzheimer’s effectively slows cognitive decline.
Ozempic and similar weight loss drugs may impact medical imaging results
GLP-1 receptor agonists alter glucose metabolism and the movement of food through the digestive system and can lead to unique uptake patterns on FDG PET-CT.

FDA clears spinal-tap test that could challenge PET in Alzheimer’s diagnostics

The FDA has approved a lab test for evaluating cognitively impaired adults who may be in the early stages of Alzheimer’s disease.

CMS coverage decision for Alzheimer's drug, related PET scans sparks concern in imaging community

In a statement released on April 14, MITA cautioned that the coverage decision will “severely limit patient access” to amyloid PET diagnostics and anti-amyloid monoclonal antibodies treatment.

coronavirus COVID-19 vaccine vaccination

FDG PET/CT radiomics distinguishes between vaccine-related or metastatic breast cancer lymphadenopathy

The findings could help clinicians manage patients’ treatment when the origin of axillary lymphadenopathy is of concern, experts suggested.

Combination therapy that includes new radionuclide proves effective for metastatic prostate cancer

The therapeutic combination of 177Lu-PSMA-617 with idronoxil (NOX66) reduced PSA levels in 86% of study participants.

MRI/PET scans link brainstem atrophy to dementia symptoms

Experts suggest that their findings could help differentiate between dementia and other neurological diseases that have similar symptoms.

New radiotracer that detects prostate cancer recurrence produces 'stunning' results

The research focused on a radiopharmaceutical that contains the isotope zirconium 89, which has a significantly longer half-life compared to gallium-68-labelled PSMA ligands.

PET scans spot brain abnormalities in long COVID patients

For 47% of patients with long COVID symptoms, brain PET scans identified mild to moderate or severe hypometabolic patterns.

FDA approves new radioligand therapy for PSMA positive metastatic prostate cancer

In clinical trials, the therapy reduced patients' risk of death by 38%, along with significantly decreasing disease progression.

PET/CT

Inflammation-targeting PET method predicts recovery after heart attack

Nuclear cardiology expands beyond perfusion imaging as it enters a new era

PET holds promise for carotid plaque assessments

Imaging offers insight into impact of new Alzheimer's treatment from Eli Lilly

Ozempic and similar weight loss drugs may impact medical imaging results